Harvest Health: Second Quarter Consensus Estimates

Harvest Health and Recreation (CSE: HARV) announced that they will be reporting their second quarter financials after the market closes on August 10.

Analysts have a consensus C$7 12-month price target on the company, via a total of 5 analysts, with one analyst having a strong buy rating, and the other 4 analysts having buy ratings. The street high comes from Alliance Global Partners with a C$9.50 price target, and the lowest target comes from Stifel-GMP with a C$5.50 price target.

Currently 4 analysts have revenue estimates for the second quarter. The mean between all 4 is $97.08 million; this number has been revised slightly higher from $87.08 million at the start of the year. The street high is $98.60 million while the lowest sits at $95.72 million.

Two analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 50.55%, with this number being revised slightly downwards from 51.70% at the start of the year. Street high goes to Stifel-GMP with a 53.50% estimate and the lowest sits at 47.60%.

Onto EBITDA estimates, there are currently 3 analysts who have second quarter EBITDA estimates. The mean is currently $26.82 million, with this number being higher than at the start of the year. Street high goes to Alliance Global with a $28.27 million EBITDA estimate and the lowest being a $26 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Is Agnico Eagle Seabridge Gold’s Mystery Lender?

This Gold Giant Is Building 1.5 Million More Ounces a Year | Agnico Eagle Q3 Earnings

This Gold Giant Was a Mess. Now It’s Back! | Barrick Mining Q3 2026 Earnings

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

CareRx: Canaccord Raises Price Target To $6.50 Following Financing

Earlier this week, CareRx Corp (TSX: CRRX) closed their C$21.2 million bought deal. Notably, $6.25...

Friday, February 5, 2021, 11:45:00 AM

Haywood Reiterates $12 Price Target On Well Health

On January 20th, Well Health (TSX: WELL) provided a business update which included fourth quarter...

Monday, January 24, 2022, 04:22:00 PM

Kirkland Lake Gold: Analyst Price Targets Lowered Due To Disappointing Guidance

Kirkland Lake Gold (TSX: KL) recently announced 2021 operating guidance and their production profile visibility...

Thursday, December 17, 2020, 02:19:00 PM

Canaccord: NG Energy Has “One Of The Largest Onshore Discoveries From The Last Few Years”

On October 20, NG Energy (TSXV: GASX) announced that it had been successful drilling the...

Saturday, October 22, 2022, 01:06:00 PM

Air Canada: BMO Remains Bullish With $30 Price Target

During the 2022 Industrial Tour de Montreal, BMO Capital Markets sat down with Air Canada...

Monday, November 21, 2022, 12:49:24 PM